Shimamura Munehisa, Sato Naoyuki, Yoshimura Shinichi, Kaneda Yasufumi, Morishita Ryuichi
Division of Clinical Gene Therapy, Graduate School of Medicine, Osaka University, Japan.
Front Biosci. 2006 Jan 1;11:753-9. doi: 10.2741/1833.
VEGF and HGF are pleiotropic factors that regulate cell growth, cell motility, and morphogenesis of various types of cells. The receptors of these growth factors are expressed in neurons and endothelial cells, and are identified as neurotrophic, neuroprotective, and angiogenic factors. Indeed, gene therapy using viral vectors encoding the VEGF or HGF gene has been reported to be effective for preventing the expansion of ischemic injury. However, the safety issue of viral vectors is a major problem in clinical application. To overcome this problem, we have developed an HVJ-based non-viral vector, which achieves high-efficiency transfection rates of viral vectors with the safety of liposomes. This review discusses the feasibility of gene therapy using an HVJ-based non-viral vector containing the VEGF or HGF gene for cerebral ischemia.
血管内皮生长因子(VEGF)和肝细胞生长因子(HGF)是多效性因子,可调节各类细胞的生长、细胞运动及形态发生。这些生长因子的受体在神经元和内皮细胞中表达,并被鉴定为神经营养、神经保护和血管生成因子。事实上,据报道,使用编码VEGF或HGF基因的病毒载体进行基因治疗可有效预防缺血性损伤的扩大。然而,病毒载体的安全性问题是临床应用中的一个主要问题。为克服这一问题,我们开发了一种基于仙台病毒(HVJ)的非病毒载体,它在具备脂质体安全性的同时,实现了病毒载体的高效转染率。本文综述讨论了使用含有VEGF或HGF基因的基于HVJ的非病毒载体进行脑缺血基因治疗的可行性。